Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | CCR3 | P51677 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19613477 | 1.00 | OPRL1 (0.58) | OPRL1POLBCYP3A4HSD17B10CCR3 | |
| Hydrochloric Acid SCHEMBL6615899 | 0.98 | POLB (0.59) | OPRL1POLBCYP3A4HSD17B10CCR3 | |
| SCHEMBL6378751 | 0.90 | CYP2D6 (0.57) | OPRL1POLBCYP3A4KMT2ASIGMAR1 | |
| SCHEMBL653329 | 0.89 | OPRL1 (0.67) | OPRL1POLBCYP3A4HSD17B10CCR3 | |
| SCHEMBL3889270 | 0.84 | CYP2D6 (0.48) | OPRL1POLBCYP3A4KMT2AGAA | |
| SCHEMBL15470506 | 0.83 | SLC6A3 (0.51) | SIGMAR1 | |
| SCHEMBL22121611 | 0.83 | OPRL1 (0.41) | OPRL1POLBCYP3A4CCR3KMT2A | |
| SCHEMBL2262610 | 0.82 | CYP3A4 (0.56) | OPRL1POLBCYP3A4HSD17B10KMT2A | |
| SCHEMBL4817148 | 0.82 | CYP3A4 (0.56) | OPRL1POLBCYP3A4HSD17B10KMT2A | |
| SCHEMBL8199005 | 0.82 | OPRL1 (0.62) | OPRL1POLBCYP3A4HSD17B10CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007117482-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | claimed |
| US-20250304577-A1 | TYK2 INHIBITORS | BIOGEN MA INC. | 2025-10-02 | — | — | US | disclosed |
| CN-119654322-A | TYK2 inhibitors | 渤健马萨诸塞州股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-114507215-B | Compound serving as PAK4 kinase inhibitor and preparation method and application thereof | 成都海博为药业有限公司 | 2024-09-13 | — | — | CN | disclosed |
| US-RE49481-E1 | Compounds for the treatment and prophylaxis of respiratory syncytial virus disease | HOFFMANN-LA ROCHE INC. (US) | 2023-04-04 | — | — | US | disclosed |
| CN-114507215-A | Compound serving as PAK4 kinase inhibitor and preparation method and application thereof | 成都海博为药业有限公司 | 2022-05-17 | — | — | CN | disclosed |
| US-11299490-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2022-04-12 | — | — | US | disclosed |
| CN-109526219-B | Benzenesulfonamides and their use as therapeutic agents | 泽农医药公司 | 2021-03-12 | — | — | CN | disclosed |
| US-20200354354-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2020-11-12 | — | — | US | disclosed |
| US-10815229-B1 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2020-10-27 | — | — | US | disclosed |
| US-5284842-A | Active against gramnegative bacteria | BAYER AKTIENGESELLSCHAFT (DE) | 1994-02-08 | — | — | US | disclosed |
| US-5252734-A | Antibacterial 5-alkylquinolonecarboxylic acids | BAYER AKTIENGESELLSCHAFT (DE) | 1993-10-12 | — | — | US | disclosed |
| US-5173484-A | Animal growth regulators | BAYER AKTIENGESELLSCHAFT (DE) | 1992-12-22 | — | — | US | disclosed |
| US-5140033-A | For prevention or treatment of bacterial infections in humans or animals | BAYER AKTIENGESELLSCHAFT (DE) | 1992-08-18 | — | — | US | disclosed |
| EP-0391132-A1 | 5-Alkylquinolinone carboxylic acids | BAYER AG (DE) | 1990-10-10 | — | — | EP | disclosed |
| EP-0326916-A2 | Quinolone- and naphthyridone-carboxylic acid derivatives, method for their preparation and antibacterial agents and food additives containing them | BAYER AG (DE) | 1989-08-09 | — | — | EP | disclosed |
| EP-0132845-B1 | NOVEL 1,8-NAPHTHYRIDINE DERIVATIVES, AND PROCESS FOR PREPARATION THEREOF | Dainippon Pharmaceutical Co., Ltd. (JP) | 1988-04-13 | — | — | EP | disclosed |
| US-4649144-A | Antibacterial 7-(3-amino-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid derivatives | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1987-03-10 | — | — | US | disclosed |
| US-4549988-A | ANTICONVULSANTS, ANTIDEPRESSANTS, MUSCLE RELAXANTS, CHEMICAL INTERMEDIATES | HOFFMANN-LA ROCHE INC. (US) | 1985-10-29 | — | — | US | disclosed |
| EP-0132845-A2 | Novel 1,8-Naphthyridine derivatives, and process for preparation thereof | Dainippon Pharmaceutical Co., Ltd. (JP) | 1985-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10815229-B1 | Benzenesulfonamide compounds and their use as therapeutic agents | SCN1A, SCN1B, SCN2B | OPRL1 1303/4885POLB 3769/4885CYP3A4 505/4885 |
| US-20250304577-A1 | TYK2 INHIBITORS | TYK2, JAK2, JAK1 | OPRL1 4404/4885POLB 2321/4885CYP3A4 3635/4885 |
| US-11299490-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | SCN1A, SCN1B, SCN2B | OPRL1 1303/4885POLB 3769/4885CYP3A4 505/4885 |
| US-20200354354-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SCN1A, SCN1B, SCN2B | OPRL1 1303/4885POLB 3769/4885CYP3A4 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.